Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
ESPR
ESPR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest ESPR ETF News Today | Earnings, Events & Price Alerts
ESPR News
Esperion Acquires Corstasis to Expand Product Line
1d ago
Benzinga
Esperion Acquires Corstasis for $75M to Enhance Cardiovascular Treatment
1d ago
seekingalpha
Esperion Acquires Corstasis, Launches First FDA-Approved Nasal Diuretic
1d ago
Newsfilter
Esperion Grants Restricted Stock Units to New Employees
Feb 11 2026
Newsfilter
Esperion Therapeutics Reports Strong 2025 Preliminary Results with $400 Million Revenue
Jan 12 2026
NASDAQ.COM
Esperion Reports $156-$160 Million in 2025 Sales, Unveils Vision 2040 Strategy
Jan 12 2026
Globenewswire
Esperion's Bempedoic Acid Recognized by ACC as First-Line LDL-C Lowering Therapy
Dec 19 2025
Globenewswire
Esperion's Bempedoic Acid Recognized by ACC for LDL-C Lowering in PAD Patients
Dec 19 2025
Newsfilter
Esperion Grants 380,000 Stock Options and 435,536 RSUs to New CCO John Harlow
Dec 09 2025
Newsfilter
Piper Sandler Upgrades Esperion to Overweight Due to CV Franchise
Nov 25 2025
SeekingAlpha
Esperion to Take Part in the 37th Annual Healthcare Conference Hosted by Piper Sandler
Nov 19 2025
Newsfilter
HLS, Esperion's Partner, Secures Health Canada Approval for NILEMDO to Reduce LDL Cholesterol
Nov 18 2025
NASDAQ.COM
DoorDash Reports Disappointing Q3 Earnings, Alongside elf Beauty, Duolingo, HubSpot, and Other Major Stocks Declining in Thursday's Pre-Market Trading
Nov 06 2025
Benzinga
Snap Shares Surge Nearly 20%; Check Out 20 Stocks Making Moves in Premarket Trading
Nov 06 2025
Benzinga
Esperion Therapeutics Reports GAAP EPS of -$0.16, Falling Short by $0.08; Revenue of $87.3M Exceeds Expectations by $9.5M
Nov 06 2025
SeekingAlpha
ESPR Seeks Diversification Through Rare Liver Disease Candidate, Shares Rise
Oct 17 2025
NASDAQ.COM
Show More News
